A phase II trial of gemcitabine in patients with advanced hepatocellular carcinoma (Q33343204)

26 July 2017

A phase II trial of gemcitabine in patients with advanced hepatocellular carcinoma (English)

1 reference

26 July 2017

phase II clinical trial

0 references

hepatocellular carcinoma

1 reference

1

Charles S Fuchs

1 reference

26 July 2017

Jeffrey W Clark

2

1 reference

26 July 2017

David P Ryan

3

1 reference

26 July 2017

Mathew H Kulke

4

1 reference

26 July 2017

Haesook Kim

5

1 reference

26 July 2017

Craig C Earle

6

1 reference

26 July 2017

Michele Vincitore

7

1 reference

26 July 2017

Robert J Mayer

8

1 reference

26 July 2017

Keith E Stuart

9

1 reference

26 July 2017

language of work or name

English

0 references

publication date

1 June 2002

1 reference

26 July 2017

1 reference

26 July 2017

94

1 reference

26 July 2017

12

1 reference

26 July 2017

3186-3191

1 reference

Review article: Overview of medical treatments in unresectable hepatocellular carcinoma--an impossible meta-analysis?

26 July 2017

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10607

Treatment of hepatocellular carcinoma: a systematic review of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10607

Antitumor effect of the nucleoside analogs 2-chlorodeoxyadenosine and 2',2'-difluorodeoxycytidine on human hepatoma HepG2 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10607

Enhancement of tumor radioresponse by combined chemotherapy in murine hepatocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10607

Phase II study of gemcitabine in patients with advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10607

Nonparametric Estimation from Incomplete Observations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10607

Clinical trials in primary hepatocellular carcinoma: current status and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10607

Phase II and pharmacokinetic study of paclitaxel therapy for unresectable hepatocellular carcinoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10607

A phase II study of irinotecan in patients with advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10607

A phase II trial of oral eniluracil/5-fluorouracil in patients with inoperable hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10607

Expression of P-glycoprotein in hepatocellular carcinoma: a potential marker of prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10607

MDR1 (multidrug resistance) gene expression in human primary liver cancer and cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10607

Apoptosis and changes in glucose transport early after treatment of Morris hepatoma with gemcitabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10607

Treatment of advanced hepatocellular carcinoma with biweekly high-dose gemcitabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10607

Rising incidence of hepatocellular carcinoma in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10607

Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma. A prospective randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10607

A phase II study of raltitrexed ('Tomudex') in patients with hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10607

21 January 2018

Identifiers

DOI

10.1002/CNCR.10607

1 reference

26 July 2017

1 reference